Potency of veterinary rabies vaccines in the netherlands: A case for continued vigilance

Veterinary Quarterly

Volumn 18, Issue 4, 1996, Pages 146-150

  Rooijakkers, E J M ^a,b   Nieuwenhuijs, J H M ^c   Vermeulen, A A ^b   van Steenis, G ^b   Osterhaus, A D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Vet Public Health Inspectorate   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ARTICLE; DRUG FORMULATION; DRUG POTENCY; IMMUNOGENICITY; MOUSE; NETHERLANDS; NONHUMAN; RABIES;

ANIMAL DISEASES; ANIMALS; CHIROPTERA; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; MICE; NETHERLANDS; NUCLEOPROTEINS; RABIES; RABIES VACCINES; RABIES VIRUS;

ANIMALIA; RABIES VIRUS;

EID: 0030319566     PISSN: 01652176     EISSN: 18755941     Source Type: Journal    
DOI: 10.1080/01652176.1996.9694637     Document Type: Article

References (32)

1. Atanasiu P, Perrin P, and Delagneau JF. Use ofan enzyme immunoassay with protein A for rabies antigen and antibody determinations. Develop Biol Stand 1980; 46: 207–15.
2. Barth R, Diderrich G, and Weinmann E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine 1988;6: 369–77.
3. Barth R, Franke V, Muller H, and Weinmann E. Purified chick-embryo-cell (PCEC) rabies vaccine: its potency performance in different test systems and humans. Vaccine 1990; 8: 41–8.
4. Barth R, Gross-Albenhausen E, Jaeger O, and Milcke L. The antibodybinding test a useful method for quantitative determination of inactivated rabies virus antigen. J Biol Stand 1981; 9: 81–9.
5. Barth R, Gruschkan H, Milcke L, Jaeger O, and Weinmann E. Validation of an in vitro assay for the determination of rabies antigen. Develop Biol Stand 1986; 64: 87–92.
6. Bourhy H, Kissi B, Lafon M, Sacramento D, and Tordo N. Antigenic and molecular characterization of bat rabies in Europe. J Clin Microbiol 1992; 30: 2419–26.
7. Dietzschold B, Wang H, Rupprecht CE, Celis E, Tollis M, Ertl H, Heber-Katz E, and Koprowski H. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci USA 1987; 84: 9165–9.
8. Dietzschold B, Tollis M, Rupprecht RE, Celis E, and Koprowski H. Antigenic variation in rabies and rabies-related viruses: Cross-protection independent of glycoprotein-mediated virus-neutralizing antibody. J Infec Dis 1987; 156: 815–22.
9. Dietzschold B, Rupprecht C, Lafon M, Tollis M, Mattei J, Wiktor TJ, and Koprowski H. Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related virus. Implications forepidemiology and control of rabies. Rev Infect Dis 1988; 10: S785–98.
10. Ferguson M, and Heath A. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use. Biologicals 1992; 20: 143–54.
11. Ferguson M, Seagroatt V, and Schild G. A collaborative study on the use of single radial immuno-diffusion for the assay of rabies virus glycoprotein. J Biol Stand 1984; 12: 283–94.
12. Ferguson M, and Schild GC. A single radial immuno-diffusion technique for the assay of rabies glycoprotein antigen: application for potency tests of vaccines against rabies. J Gen Virol 1982; 59: 197–201.
13. Fitzgerald EA, Gallagher M, Hunter WS, and Seligmann Jr. EB. Use of the antibody assay in immunized mice for the determination of rabies vaccine potency. Develop Biol Stand 1978; 40: 183–6.
14. Fu ZF, Dietzschold B, Schumacher CL, Wunner WH, Ertl HCJ, and Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc Natl Acad Sci USA 1991; 88: 2001–5.
15. Lafon M, Bourhy H, and Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine 1988; 6: 362–8.
16. Lafon M, Herzog M, and Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage). Lancet 1986; ii: 515.
17. Lyng J, Wies Bentzon M, Ferguson M, and Fitzgerald EA. Rabies vaccine standardization: International Collaborative study for the characterization of the fifth International Standard for rabies vaccine. Biologicals 1992; 20: 301–13.
18. Monograph European Pharmacopoeia. Vaccinum rabiei inactivatum ad usum veterinarium. Monograph European Pharmacopoeia, 2nd Edn, 1985; part 11/9: 451.
19. Montaiio-Hirose JA; Bourhy H, and Lafon M. A reduced panel of antinucleocapsid monoclonal antibodies for bat rabies virus identification in Europe. Res Virol 1990; 141: 571–81.
20. Oirschot JT van. Institute for Animal Science and Health, Lelystad, The Netherlands. Personal communication.
21. Osterhaus ADME, Groen J, UytdeHaag FGCM, Bunschoten EJ, Groot IGM de, Meer R van der, and Steenis G van. Quantification of rabies virus vaccine glycoprotein by ELISA with monoclonal antibodies: correlation with single radial diffusion and the induction of anti-viral antibodies and protection in mice. In: Progress in Rabies Control (Eds Thraenhart O, Koprowski H, Btigel K, and Sureau P), Staples Printers Rochester Ltd, Rochester, 1990: 320–3.
22. Perrin P, Morgeaux S, and Sureau P. In vitro rabies vaccine potency appraisal by ELISA: Advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. Biologicals 1990; 18: 321–30.
23. Perrin P, Versmisse P, and Sureau P. Use of monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay. J Biol Stand 1985; 13: 295–301.
24. Rabies Surveillance Report, April-June 1987. In: Rabies Bulletin Europe 2/87, WHO Collaborating Centre for Rabies Surveillance and Research.
25. Rooijakkers EJM, Uittenbogaard JP, Groen J, and Osterhaus ADME. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J Virol Meth (in press)
26. Seligmann EB Jr. The NIH test for potency. In: Laboratory Techniques in Rabies (Eds Kaplan MM, and Koprowski H), 3rd Edn, World Health Organization, Geneva, 1973; pp. 279–86.
27. Sureau P. Contribution to rabies prevention. Vaccine 1992; 10: 896–9.
28. Takita-Sonoda Y, Fujii H, Ito Y, Hiraga M, Nishizono A, Mannen K, and Minamoto N. Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection. Arch Virol 1993; 132: 51–65.
29. Thraenhart 0, and Ramakrishnan K. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera. J Biol Stand 1989; 17: 291–301.
30. Tollis M, Dietzschold B, Viola CB, and Koprowski H. Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine, 1991; 9: 134–6.
31. Van der Marel P, and Wezel AL van. Quantitative determination of rabies antigen by ELISA. Develop Biol Stand 1981; 50: 267–75.
32. WHO Expert Committee on Rabies. 8th report. WHO Technical Report Series 824, World Health Organization, Geneva, 1992.